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Abstract: Introduction: Aluminium phosphide (Alp) poisoning mortality rate has been reported as high as 70-100%, and
refractory hypotension and cardiogenic shock are the two most common presentations leading to death. Due to
lack of specific antidote, all treatments are focused on supportive care and recently, intra-aortic balloon pump
(IABP) has been suggested to treat cardiogenic shock resulting from toxic myocarditis. In the current paper,
we introduce three Alp poisoned patients for whom IABP was applied to manage their refractory shock. Case
presentation: Two men and one woman who were admitted to emergency department (ED) of Imam Reza aca-
demic Hospital, Mashhad, Iran due to intentional Alp poisoning are reported. The cases visited the ED shortly
after ingestion and nearly all of them showed hypotension, tachycardia and metabolic acidosis during early hos-
pitalization. Due to persistent shock state, despite receiving intravenous fluid therapy and vasopressor agents,
IABP insertion was performed in these cases. Finally, one of them survived and the other two died. Conclusion:
It still cannot be decided whether IABP insertion is effective in cases of Alp poisoning or not. It might be rea-
sonable to try this intervention along with other conservative treatments in patients who survive more than 12
hours and consistently suffer from refractory hypotension.
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1. Introduction
Aluminium phosphide (Alp), the main component of “Rice
Tablet”, is frequently used as a rodenticide, fumigant and
pesticide (1-5). It is easily available in some countries such
as Iran and India, and as a result many cases of suicide at-
tempts have been reported with Alp in these countries (5,
6). The exact mechanism of toxicity is not clear, but release
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of phosphine gas and subsequent cellular events including
cytochrome oxidase inhibition and oxidative stress are pro-
posed as the possible mechanism (7, 8). Mortality rate of
Alp poisoning has been reported as high as 70-100%, and
refractory hypotension and cardiogenic shock are the two
most common presentations leading to death (9, 10). Due to
lack of specific antidote, all treatments are focused on sup-
portive care and researches are still in progress to make ad-
vancements in Alp poisoning management (11-15). Recently,
intra-aortic balloon pump (IABP) has been suggested to treat
cardiogenic shock resulting from toxic myocarditis following
various poisonings (16, 17). There are some reports of IABP
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insertion regarding Alp poisoning, some successful and some
not (18, 19). In the current paper, we introduce three Alp poi-




A 20-year-old man who ingested Alp (5 grams of 56% pow-
der) was admitted to ED with nausea, vomiting, diarrhea and
abdominal pain. He was confused on admission. Vital signs
were as follows: blood pressure (BP) =75/45 mmHg; respi-
ratory rate (RR) = 35/minute; pulse rate (PR) = 100/minute;
and oxygen saturation (SpO2) = 93% (in room air). Intra-
venous (IV) fluid therapy by normal saline 0.9% in addi-
tion to dopamine infusion was initiated. Six hours later,
BP and SpO2 had dropped to 70/pulse and 90%, respec-
tively, and PR had increased to 110/minute. Arterial blood
gas (ABG) assessment revealed pH=6.9 and Hco3=8 mEq/L.
Four vials of sodium bicarbonate were infused. Twelve hours
later, he was admitted to intensive care unit (ICU) due to
persistent hypotension and hypoxemia, as well as ventric-
ular systoles, atrial fibrillation (AF) and left bundle branch
block (LBBB) in electrocardiogram (ECG). On admission to
ICU, vital signs were PR=120/minute, BP=79/45 mmHg and
SpO2=88%. Fourteen hours after ingestion, he was intubated
because of persistent shock state despite IV fluid therapy and
administration of norepinephrine 20 micrograms/minute in
addition to dopamine 5 to 15 microgram/kg/min. Thereafter,
0.5 mg digoxin was injected due to AF rhythm and low BP.
Dilation of left ventricle and ejection fraction (EF) less than
25% was reported in echocardiography. IABP was inserted
18 hours after ingestion and after 97 hours on the 5th day of
admission, it was removed as BP and EF had improved. In
echocardiography, which was performed on the 9th day, EF
was normal, but pulmonary arterial pressure (PAP) was 75
mmHg and right ventricle was dilated, and following cardi-
ologist consultation, sildenafil and milrinone were initiated.
Echocardiography revealed normal values on day 14. He was
discharged with normal vital signs and laboratory test results.
2.2. Case 2
A 30-year-old woman was admitted to ED 2 hours after in-
gestion of half an Alp tablet. Vital signs on admission in-
cluded: BP=95/70 mmHg, RR=14/minute, PR=77/minute,
and SpO2=97% (in room air). She was admitted to ICU 6
hours later due to refractory hypotension despite adminis-
tration of IV fluid therapy and vasopressor agents. On ad-
mission to ICU pulse rate was 114/minute and SBP/DBP
was 80/50 mmHg. ABG revealed: SpO2=93%, pH=7.28,
pCO2=16.5, HCO3=7.8 mEq/L and ScVO2=45%. She received
IV fluid therapy, norepinephrine and dopamine, digoxin 0.5
mg, NAC (9 grams within 1 hour, 3 grams within 4 hours and
4 grams within 16 hours), vitamin C 1 gram/day, Calcium
gluconate 1 gram every 8 hours. Finding of echocardiogra-
phy was LVEF=30 -35%. She was intubated 12 hours after in-
gestion due to respiratory distress and SpO2 less than 88%
despite oxygen therapy by reserve bag. IABP was inserted
11 hours later. After 24 hours, she developed ventricular ar-
rhythmia and amiodarone and lidocaine were administered.
After 40 hours and despite correction of acidosis, she sud-
denly developed cardiac arrest and after two times of CPR,
was announced dead.
2.3. Case 3
A 17-year-old man was admitted to ED due to consumption
of one Alp tablet 2.5 hours before admission. Vital signs
were: RR=1 /min, O2sat=95% (in room air), PR=77/min and
BP=65/pulse mmHg on admission. Seven hours later he was
transferred to ICU. On admission to ICU blood pressure was
not detectable, PR=120/min and SpO2=80%. ABG revealed
pH=7.18, pCO2=44.7, HCO3=16.8 mEq/L and ScVO2=50%.
He received IV fluid therapy in addition to infusion of nore-
pinephrine and dopamine, digoxin 0.5 mg IV, vitamin E
100mg/daily, Vitamin C 1 gram/daily, dexamethasone and
NAC (9 gram in one hour, 4 grams in 4 hours and 6 grams in
16 hours). Hypotension was refractory to hydration and infu-
sion of high dose vasopressors. ECG revealed invert T in V3 to
V6 leads and echocardiography showed global hypokinesia
and LVEF=10-15%. IABP was inserted 4 hours after admis-
sion and in the next hour he was intubated. Systolic blood
pressure was below 6 mmHg despite correction of acidosis
and other supportive cares. Twenty hours after ingestion he
developed sudden cardiopulmonary arrest and after 45 min-
utes of CPR he died.
3. Discussion
Lethal dose of Alp is about 500 mg of a tablet (about a sixth
of a tablet). Some factors might influence prognosis of pa-
tients for example length of exposure of tablet to air, whether
it is solved in water or not and length of exposure to water;
all these factors affect the rate of phosphine gas release be-
fore it is consumed. The most important complications of
Alp poisoning are cardiovascular problems and in particu-
lar toxic myocarditis that might lead to severe heart dysfunc-
tion. However, cardiac function may be restored if the pa-
tient survives (20). It was reported that use of IABP could
be successful in some cases of acute poisoning with severe
cardiac dysfunction (21, 22). It seems that, for the first time,
IABP was inserted in a 25 year old woman with severe toxic-
ity of Alp (consumption of 10 tablets) in 2008, which was not
successful (22). Siddaiah et al. reported the first successful
use of IABP in a 22-year-old woman with cardiogenic shock
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following Alp consumption (16). Subsequently, the second
successful use was reported by Mehrpour et al. in a 24-year-
old woman in 2013 (7). Annually, about 300 cases of Alp poi-
soning are referred to Imam Reza hospital, to which these 3
cases were admitted, and most of the cases are admitted to
ICU. Due to the high rate of mortality in this type of poison-
ing and also a documented antidote not being available while
there are some reports of successful treatment with IABP, we
decided to apply IABP for our cases in addition to other sup-
portive cares. We used IABP in three cases and it was success-
ful in one case and he was discharged from hospital without
any complication; yet we did not have success in the other
two cases and both died. All cases consumed Alp intention-
ally. More investigations are still needed to decide if IABP in-
sertion is effective or not in cases of Alp poisoning. However,
the method of selecting appropriate cases is a matter of de-
bate and needs to be investigated more.
4. Conclusion:
It still cannot be decided whether IABP insertion is effective
in cases of Alp poisoning or not. It might be reasonable to try
this intervention along with other conservative treatments in
patients who survive more than 12 hours and consistently
suffer from refractory hypotension.
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